{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:18:55Z","timestamp":1784081935322,"version":"3.55.0"},"reference-count":77,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T00:00:00Z","timestamp":1353283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:sec><jats:label\/><jats:p>Over the past 30 years, many drugs have been studied as possible treatments for Alzheimer's disease, but only four have demonstrated sufficient efficacy to be approved as treatments, of which three are in the same class. This lack of success has raised questions both in the pharmaceutical industry and academia about the future of Alzheimer's disease therapy. The high cost and low success rate of drug development across many disease areas can be attributed, in large part, to late\u2010stage clinical failures (Schachter and Ramoni, Nat Rev Drug Discov 2007;6:107\u20138). Thus, identifying in phase II, or preferably phase I, drugs that are likely to fail would have a dramatic impact on the costs associated with developing new drugs. With this in mind, the Alzheimer's Association convened a Research Roundtable on June 23 and 24, 2011, in Washington, DC, bringing together scientists from academia, industry, and government regulatory agencies to discuss strategies for improving the probability of phase II trial results predicting success when considering the go\/no\u2010go decision\u2010making process leading to the initiation of phase III.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.jalz.2012.02.002","type":"journal-article","created":{"date-parts":[[2012,11,16]],"date-time":"2012-11-16T08:03:01Z","timestamp":1353052981000},"page":"39-49","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Improving Alzheimer's disease phase II clinical trials"],"prefix":"10.1002","volume":"9","author":[{"given":"Barry D.","family":"Greenberg","sequence":"first","affiliation":[{"name":"Division of Neuroscience Drug Discovery and Development University Health Network Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Carrillo","sequence":"additional","affiliation":[{"name":"Medical &amp; Scientific Relations Alzheimer's Association Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Ryan","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gold","sequence":"additional","affiliation":[{"name":"Allon Therapeutics Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Gallagher","sequence":"additional","affiliation":[{"name":"GE Healthcare Wauwatosa WI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grundman","sequence":"additional","affiliation":[{"name":"Global R&amp;D Partners, LLC San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Berman","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Wallingford CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Ashwood","sequence":"additional","affiliation":[{"name":"AstraZeneca S\u00f6dert\u00e4lje Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Siemers","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Lilly Research Laboratories Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,11,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2246"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.286"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1470"},{"key":"e_1_2_6_5_1","first-page":"CD001499","article-title":"Physostigmine for Alzheimer's disease","author":"Coelho F","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402800612"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-0102(02)00201-8"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3181e56d30"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1044-7431(03)00217-3"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(03)00320-5"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(02)03140-2"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.131152998"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21345"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-101311"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-8-54"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e31815d1048"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1866"},{"key":"e_1_2_6_18_1","first-page":"31","article-title":"Modulation of NMDA receptor by huperzine A in rat cerebral cortex","volume":"20","author":"Wang XD","year":"1999","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0022-3565(24)38024-3","article-title":"Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment","volume":"288","author":"Ye JW","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000085387"},{"key":"e_1_2_6_21_1","first-page":"941","article-title":"Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo\u2010controlled, double\u2010blind, randomized trial","volume":"82","author":"Zhang Z","year":"2002","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318216eb7b"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-100183"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2006.02.015"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720507781788882"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-009-0217-4"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000244346.08950.64"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61046-6"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1017972709652"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61074-0"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2009.07.032"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000054469"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2005.03.016"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200511000-00005"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500369"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1159\/000318845"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21623"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt30"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.8.1031"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.6.1092"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/15.5.267"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02191587"},{"key":"e_1_2_6_43_1","first-page":"231","article-title":"Isoform 4 of apolipoprotein E and Alzheimer disease. Specificity and clinical study [in French]","volume":"151","author":"Mahieux F","year":"1995","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_6_44_1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3233\/JAD-2004-6602","article-title":"Is there a characteristic lipid profile in Alzheimer's disease?","volume":"6","author":"Sabbagh M","year":"2004","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_6_45_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/156720506776383013","article-title":"Studies on the effect of the apolipoprotein E genotype on the lipid profile in Alzheimer's disease","volume":"3","author":"Sabbagh MN","year":"2006","journal-title":"Curr Alzheimer Res"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.9.1053"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.5.753"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2006.00690.x"},{"key":"e_1_2_6_49_1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman HH","journal-title":"Neurology"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/22124"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/78682"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c67808"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70043-0"},{"issue":"4","key":"e_1_2_6_54_1","first-page":"S134","article-title":"Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease","volume":"6","author":"Blennow K","year":"2010","journal-title":"Alzheimers Dement"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"},{"issue":"4","key":"e_1_2_6_56_1","first-page":"T774","article-title":"P4\u2010346: safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease","volume":"4","author":"Siemers ER","year":"2008","journal-title":"Alzheimers Dement"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2010.01.018"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.033399"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2007.12.021"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1510"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1159\/000017092"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.131482"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2006.04.088"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2006-9404"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318207b1b9"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00018-3"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543400802677240"},{"issue":"5","key":"e_1_2_6_68_1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease","volume":"132","author":"Jack CR","year":"2009","journal-title":"Brain"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70299-6"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.204008"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.1.59"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70167-4"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70355-6"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.08.025"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.55"},{"key":"e_1_2_6_78_1","first-page":"25","author":"Alzheimer's Disease International","year":"2009","journal-title":"World Alzheimer's Report"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526012000490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526012000490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.jalz.2012.02.002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2012.02.002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.jalz.2012.02.002","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2012.02.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:49:39Z","timestamp":1759942179000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1016\/j.jalz.2012.02.002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,19]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1016\/j.jalz.2012.02.002"],"URL":"https:\/\/doi.org\/10.1016\/j.jalz.2012.02.002","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,19]]},"assertion":[{"value":"2012-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}